Financial intelligence for Asia's healthcare markets
Remember me:

Analysis: Private equity flocks to healthcare

Amid questions about the direction of the global economy, investors doubled down on healthcare as a safe haven in 2016, driving up both the number and the value of deals, according to Bain & Company’s sixth Global Healthcare Private Equity and Corporate M&A Report.

Yet, with so much interest in overall healthcare assets, they faced intense competition for deals. This heated struggle bid up valuations and forced healthcare investors to get creative. Many funds took advantage of a disparity between public and private valuations for some healthcare assets, which prompted a surge in public-to-private transactions. The flip side of this trend was a falloff in the number of IPOs, amid a modest decline in overall exit activity.

In sharp contrast to the broader decline in PE deal-making, healthcare PE activity soared globally with disclosed deal values reaching US$36.4 billion in 2016, its highest level since 2007. That marked a nearly 60% increase from the total of US$23.1 billion in 2015. In Asia Pacific, activity was also strong, especially in the provider sector where deal count nearly tripled and there were a total of 52 buyouts, a return to levels last seen in 2013.

“As a long-term bet, healthcare is hard to beat,” said Kara Murphy, a partner in Bain’s Global Healthcare and Private Equity Practices and co-author of the report. “Deal activity will continue to be high as more funds look to deploy capital into the sector. Given the intense competition, funds will need to be increasingly creative to get deals done.”

After three consecutive record-setting years, total deal value in the Asia Pacific region declined somewhat in 2016, to US$3.2 billion from US$4.9 billion in 2015. The falloff was largely due to the lack of a megadeal such as the US$3.3 billion buyout of publicly traded WuXi PharmaTech that dominated 2015. The few mega scale assets that became available in 2016 went to corporate buyers. That said, underlying momentum was strong, with 10 buyouts last year valued at more than US$100 million and an additional US$700 million of the region’s capital was deployed in private investments in public equities.

PE investors continue to find Asia-Pacific’s demographics promising supported by both a growing and aging population, an expanding middle-class and rising burden of both chronic and communicable diseases. This resurgence in deal activity across the region was led by the provider sector, with 31 provider deals in 2016, about three times the number in 2015.

“Healthcare is becoming a go to destination for financial investors in Asia Pacific” said Vikram Kapur, Bain partner and leader of the firms APAC Healthcare practice. “The attractive fundamentals of the sector are bolstered by the fact that, today, assets in the region are reaching the scale that gets more and more PE investors to take notice.”

So what should we expect this year?

“Investors can expect more volatility in 2017,” said Nirad Jain, a partner in Bain’s Global Healthcare and Private Equity Practices and the report’s co-author. “As the turmoil continues, so too will the attractiveness of healthcare as a safe-haven investment. With an aging and ailing global population, demand for healthcare services will rise regardless of whether there are economic headwinds, tailwinds or crosswinds. But, that’s not to say all healthcare investors will have smooth sailing – sky-high valuations for healthcare assets mean that there are choppy waters to navigate.”

In this environment, deal makers will need to continue to be creative and look harder to find targets that have the capacity to deliver meaningful returns.

“In Asia Pacific, the coming of age of assets and growing competition from PE and corporates will continue to raise the bar for investors and they will need to think hard about the differential value add they can bring to targets beyond growth capital” added Kapur.

Posted on: 20/04/2017 UTC+08:00


Medical diagnostic imaging services provider Capitol Health has said that it expects to return to profitability in the next financial year and has upgraded its outlook for the year.
Paragon Care, a leading distributor and manufacturer supplying medical equipment to hospitals, has said that it is “targeting strong growth in 2018 across all key metrics”.
Malaysian medical glove manufacturer Supermax Group has reported a 42.8% jump in Q1 profits to M$27.9 million (US$6.8 million) on revenues that 16% to M$312 million.
At its annual general meeting, international pathology, imaging and medical centres operator Sonic Healthcare reaffirmed guidance for the year. Chief executive Colin Goldschmidt said that the first quarter of the 2019 financial year confirmed expectations that underlying earnings would grow between 6% and 8% on a constant currency basis.
It has been another great quarter for China Cord Blood Corporation (CCBC), the country’s largest provider of cord blood storage and ancillary services. For the second quarter in a row, profits more than doubled. They came in at US$10.2 million.
New Zealand-based medical device manufacturer Fisher & Paykel Healthcare has reported a steady set of first half figures. Profits were up 4% to NZ$81.3 million (US$55.3 million) on revenues that rose 8% to NZ$458.4 million.
Retirement village operator Arvida has reported a 14.5% slump in profits for the first half of the year to NZ$14.5 million (US$9.9 million). At the same time, revenues were up 27.9% to NZ$60 million.
Medical device manufacturer Microport Scientific Corporation plans to acquire the cardiac rhythm management (CRM) business of London-based medical device manufacturer LivaNova for US$190 million.


The promise of a bottom in Singapore’s office market has caused its ranking as an investment market to soar from next-to-bottom last year to third in this year’s “Emerging Trends in Real Estate Asia Pacific 2018” report, a real estate forecast jointly published by the Urban Land Institute (ULI) and PwC.
Kamal Brar, vice president and general manager of Asia Pacific for data software company Hortonworks, looks at how data analytics can provide effective and affordable healthcare in Singapore.
The latest Sun Life Financial Asia Diabetes Awareness Study reveals an alarming knowledge gap in diabetes. A third of Asian women who are or were pregnant in the past three years are unaware of the risk of developing gestational diabetes in pregnancy, while one in seven births in Asia is currently affected by gestational diabetes.
Gan Kim Yong, Singapore’s minister for health, explains why the private sector needs to get behind the National Electronic Health Record System.
Business leaders in Asia Pacific’s healthcare industry are showing urgency in embracing the fourth industrial revolution, according to the Microsoft Asia Digital Transformation Survey. More than three-quarters of them believe that they need to transform to a digital business to enable future growth and yet only a quarter said that they have a full digital strategy in place today.
An agreement for an additional US$15 million funding from the World Bank will be used to expand health and nutrition coverage in the Lao People's Democratic Republic. It is expected to benefit more than 1 million people across 14 provinces.
Bart Van den Mooter, CEO of the TforG Group, looks at the drivers behind the rapid growth in Asia’s medical tourism market.
The ambitious healthcare agenda under Moon Jae-in's liberal presidency will seek to expand national health insurance reimbursement and limit the burden of excessive medical costs, while overhauling the healthcare system. BMI Research looks at the winners and the losers in the presidential agenda.




Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices